Regulus Therapeutics up on starting preclinical ALS studies

Regulus Therapeutics

24/03/2022 13:19

** Drug developer's shares  RGLS.O  rise 3.5% to $0.29
premarket 
    ** Co initiates preclinical studies of certain compounds to
test their potential to treat Amyotrophic Lateral Sclerosis
(ALS) (https://refini.tv/3uskC8r)
    ** ALS is a progressive nervous system disease that causes
loss of muscle control as it affects nerve cells in the brain
and spinal cord
    ** Study is being undertaken under a collaboration agreement
with Harvard's Brigham and Women's Hospital; agreement has been
effective since September 2021
    ** Compounds have been designed by Regulus to inhibit
activity of the gene miR-155, which plays an important role in
the pathogenesis of ALS
    ** Study plan focuses on evaluation of the compounds in
microglia cell-based assays and in animal models of the disease,
to identify potential candidates to advance into further studies
    ** Preliminary data expected in second half of 2022
    ** Up to last close, stock had fallen ~9% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))